Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women.

Trial Profile

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2012

At a glance

  • Drugs Valaciclovir (Primary) ; Metronidazole
  • Indications Bacterial vaginosis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Planned initiation date changed from Jun 2008 to Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top